Pharmaceuticals
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review ...
2025-09-23 10:22
2095
IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training
MELBOURNE, Australia, Sept. 23, 2025 /PRNewswire/ -- IMRA Surgical, an Australian-based company at the forefront of disruptive technology for surgical training solutions announces a collaboration with Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") a global leader in radiopharmaceu...
2025-09-23 05:19
2414
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS
2025-09-22 20:00
2526
Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First Dedicated Cancer Centre for Women
NEW DELHI, Sept. 22, 2025 /PRNewswire/ -- Apollo Hospitals Enterprise Ltd (AHEL) recently announced the launch ofApollo Athenaa – Asia's First Dedicated Cancer Centre for Women, located in E2-E3, Defence Colony, New Delhi. The centre was inaugurated by the Hon'ble Chief Minister ofDelhi, Smt. Rek...
2025-09-22 15:43
3475
First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 onSeptember 19, ...
2025-09-22 12:29
5280
Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic m...
2025-09-19 20:00
3443
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg...
2025-09-19 19:59
6272
LabConnect Appoints Bill Finger as Senior Vice President, Global Strategic Services
JOHNSON CITY, Tenn., Sept. 19, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Bill Finger as Senior Vice President, Global Strategic Services, effectiveWednesday, September 10, 2025. Bill brings more than 25 years of diagnostics and clinical research experience, with ...
2025-09-19 01:25
2409
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile SKY-0515's Phase 2/3 FALCON-HD t...
2025-09-17 20:44
2067
Malaysia Healthcare Week Debuts in Kuwait, Strengthening Malaysia-Kuwait Medical Partnership
Spearheaded by the Malaysia Healthcare Travel Council, the event builds momentum towards the Malaysia Year of Medical Tourism 2026. KUWAIT CITY, Kuwait, Sept. 17, 2025 /PRNewswire/ -- Building on Malaysia's established reputation as a premier global healthcare destination and as part of the stra...
2025-09-17 10:01
3453
ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine
MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its RELIEV-CM Pilot Study. The findings demonstrate sustaine...
2025-09-16 19:00
1993
SI GROUP TO SHOWCASE SUSTAINABLE ADDITIVE INNOVATIONS AT K 2025
Industry Leader Presents Advanced Solutions for Plastics and Rubber THE WOODLANDS, Texas, Sept. 15, 2025 /PRNewswire/ -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, will showcase its portfolio of ...
2025-09-15 20:30
2913
Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc
Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 /PRNewswi...
2025-09-15 12:06
1944
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initi...
2025-09-15 08:00
2959
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
* 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025). * The newly released results, based on clinical practices at several leading hospitals inChina, offer a comprehensive overview of the efficacy and safety of NEFE...
2025-09-15 07:45
5808
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharm...
2025-09-12 09:51
2215
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
* Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) *...
2025-09-11 14:56
2014
Fosun International Recognized among Fortune's 2025 "Most Admired Chinese Companies" List
HONG KONG, Sept. 11, 2025 /PRNewswire/ -- On 9 September, Fortune China magazine released its 2025 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highligh...
2025-09-11 09:00
3754
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation ...
2025-09-10 07:01
2278
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
2025-09-09 20:42
6393
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
8485
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
8430
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
8349
